Myasthenia Gravis News and Research

RSS
Myasthenia gravis is a chronic autoimmune neuromuscular disease characterized by varying degrees of weakness of the skeletal (voluntary) muscles of the body. The hallmark of myasthenia gravis is muscle weakness that increases during periods of activity and improves after periods of rest. Muscles that control eye and eyelid movements, facial expression, chewing, talking, and swallowing are often, but not always, involved. The muscles that control breathing and neck and limb movements may also be affected. Myasthenia gravis is caused by a defect in the transmission of nerve impulses to muscles. Normally when impulses travel down the nerve, the nerve endings release a neurotransmitter substance called acetylcholine. In myasthenia gravis, antibodies produced by the body's own immune system block, alter, or destroy the receptors for acetylcholine. The first noticeable symptoms of myasthenia gravis may be weakness of the eye muscles, difficulty in swallowing, or slurred speech. Symptoms vary in type and severity. Myasthenia gravis is not directly inherited nor is it contagious.
How do viral infections cause autoimmune diseases?

How do viral infections cause autoimmune diseases?

Researcher contextualizes a study on IgG4 anti-Spike levels after repeated SARS-CoV-2 mRNA vaccination

Researcher contextualizes a study on IgG4 anti-Spike levels after repeated SARS-CoV-2 mRNA vaccination

Study shows potential benefits of efgartigimod as a treatment for immune thrombocytopenia

Study shows potential benefits of efgartigimod as a treatment for immune thrombocytopenia

Defense department health plan cuts its pharmacy network by nearly 15,000 outlets

Defense department health plan cuts its pharmacy network by nearly 15,000 outlets

Researchers explore single-cell sequencing technologies to understand molecular mechanisms of autoimmune diseases

Researchers explore single-cell sequencing technologies to understand molecular mechanisms of autoimmune diseases

Immune-mediated inflammatory diseases following COVID-19

Immune-mediated inflammatory diseases following COVID-19

Rheumatoid arthritis drug can reduce the risk of deterioration in myasthenia gravis

Rheumatoid arthritis drug can reduce the risk of deterioration in myasthenia gravis

Gait analysis in animals: Treadmill versus non treadmill system

Gait analysis in animals: Treadmill versus non treadmill system

Unlocking the power of proteins to better understand human health

Unlocking the power of proteins to better understand human health

UC San Francisco neurologists focus on the hazards of abortion restrictions for women of reproductive age

UC San Francisco neurologists focus on the hazards of abortion restrictions for women of reproductive age

The effects and mechanisms of SARS-CoV-2 on the nervous system

The effects and mechanisms of SARS-CoV-2 on the nervous system

Study finds increased risk of neurodegenerative disorders among COVID-19 positive patients

Study finds increased risk of neurodegenerative disorders among COVID-19 positive patients

Type I interferons play crucial role in fending off SARS-CoV-2

Type I interferons play crucial role in fending off SARS-CoV-2

Current evidence that vitamin D is effective against COVID-19 neurological sequelae

Current evidence that vitamin D is effective against COVID-19 neurological sequelae

TTUHSC expert wins NIH renewal grant to continue research on neurological disorders

TTUHSC expert wins NIH renewal grant to continue research on neurological disorders

New research shines light on mysterious dynamics that define the interplay between nerves and muscle

New research shines light on mysterious dynamics that define the interplay between nerves and muscle

Model of neuromuscular junction could accelerate new treatments for neuromuscular diseases

Model of neuromuscular junction could accelerate new treatments for neuromuscular diseases

Black patients with systemic sclerosis may experience poorer outcomes more often than others

Black patients with systemic sclerosis may experience poorer outcomes more often than others

Dying patients with rare diseases struggle to get experimental therapies

Dying patients with rare diseases struggle to get experimental therapies

Study fills crucial knowledge gaps on myasthenia gravis

Study fills crucial knowledge gaps on myasthenia gravis